This revised AATS Expert Consensus Document evaluates updated best-practice standards for staging, diagnosis, neoadjuvant treatment, surgical management, and postoperative therapy of early-stage non–small cell lung cancer (NSCLC), incorporating evidence published since the 2023 original document.
Key updates include: (1) additional RCT evidence supporting preoperative or perioperative chemoimmunotherapy, (2) adjuvant targeted therapy for eligible patients with actionable mutations, and (3) evolving standards for adjuvant immunotherapy in previously untreated patients; multidisciplinary evaluation and molecular diagnostics remain strongly emphasized.
As a consensus document rather than a primary study, recommendations reflect expert interpretation of available data and may lag behind rapidly evolving trial evidence; no original patient-level data or statistical outcomes are reported.
For patients with early-stage NSCLC, clinicians should pursue accurate molecular staging and involve a multidisciplinary team; perioperative chemoimmunotherapy is now supported by multiple RCTs, and adjuvant targeted therapy should be offered to eligible patients with actionable mutations.
Explore related topics
